(Q37963572)

26 August 2017

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects (English)

1 reference

26 August 2017

1 reference

1

Anthony H V Schapira

1 reference

26 August 2017

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

25

1 reference

26 August 2017

12

1 reference

26 August 2017

1061-1071

1 reference

https://scigraph.springernature.com/pub.10.2165/11596310-000000000-00000

26 August 2017

0 references

cites work

Drug selection and timing of initiation of treatment in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Deprenyl in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Safinamide in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Improvement of motor function in early Parkinson disease by safinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Mitochondrial complex I deficiency in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Oxidative stress and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Oxidative stress in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

The relevance of preclinical studies for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Molecular and clinical prodrome of Parkinson disease: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Why have we failed to achieve neuroprotection in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Clinical trials of neuroprotection for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Science, medicine, and the future: Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Neurobiology and treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Movement disorders: advances in cause and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Treatment options in the modern management of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Perspectives on recent advances in the understanding and treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Delayed development of symptomatic improvement by (−)-deprenyl in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596310-000000000-00000

Selegiline slows the progression of the symptoms of Parkinson disease

21 January 2018

1 reference

12 December 2020

Parkinson disease: Parkinson disease clinical subtypes and their implications

1 reference

12 December 2020

The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo

1 reference

12 December 2020

Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Challenges to the development of disease-modifying therapies in Parkinson's disease

1 reference

12 December 2020

Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium

1 reference

12 December 2020

1 reference

12 December 2020

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

1 reference

12 December 2020

L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.

1 reference

12 December 2020

Selegiline enhances survival and neurite outgrowth of MPP(+)-treated dopaminergic neurons

1 reference

12 December 2020

Levodopa in the treatment of Parkinson's disease

1 reference

12 December 2020

Molecular basis of mitochondrial myopathies: polypeptide analysis in complex-I deficiency

1 reference

12 December 2020

Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

1 reference

12 December 2020

Mitochondrial complex I deficiency in Parkinson's disease

1 reference

12 December 2020

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

10.2165/11596310-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22133327

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22133327